Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 InsertionsNicolas Floc’h, Darren A.E. Cross, Anna D. Staniszewska et al.|Molecular Cancer Therapeutics|2018Cited by 113
Antitumor activity of osimertinib in NSCLC harboring EGFR exon 20 insertions.Jonathan W. Riess, Darren A.E. Cross, Nicolas Floc’h et al.|Journal of Clinical Oncology|2017Cited by 8